Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
July 10, 2024 17:30 ET
|
Avicanna Inc.
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna General Meeting
June 19, 2024 17:30 ET
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
June 19, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
June 18, 2024 07:45 ET
|
Avicanna Inc.
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
May 14, 2024 07:35 ET
|
Avicanna Inc.
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox™...
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
May 13, 2024 07:30 ET
|
Avicanna Inc.
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. ...
Avicanna Announces Closing of Non-brokered Private Placement
April 18, 2024 17:00 ET
|
Avicanna Inc.
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
April 10, 2024 08:37 ET
|
Avicanna Inc.
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna Reports Full Year 2023 Audited Financial Results
April 02, 2024 07:30 ET
|
Avicanna Inc.
$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna...
Avicanna anuncia el lanzamiento en Canadá de una formulación de su propiedad con un 10% de CBD (sin THC)
March 28, 2024 07:30 ET
|
Avicanna Inc.
La formulación oral con un 10% de CBD (sin THC) se comercializa como RHO Phyto Micro Drop 100 en Canadá. RHO Phyto Micro Drop 100 está disponible exclusivamente en MyMedi.ca. TORONTO, March 28,...